ProQR director Theresa Heggie Form 3 holdings

ProQR Therapeutics N.V. director Theresa Heggie filed an initial ownership report showing option-based and share holdings in the company.

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Theresa Heggie filed an initial ownership report showing option-based and share holdings in the company. She directly holds several "Share Option (Right to Buy)" awards on Ordinary Shares, including 100,000 underlying shares at an exercise price of $6.73 expiring on October 31, 2033, alongside other options with exercise prices ranging from $0.67 to $9.91 and expirations through 2035. She also directly holds 43,623 Ordinary Shares. Footnotes state that one option grant is fully vested and others vest 25% on specified dates with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service.

Insider Trade Summary

11 transactions reported

Mixed 11 txns

Insider HEGGIE THERESA

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 405,565 contracts (Direct); Ordinary Shares — 43,623 shares (Direct)

Footnotes (5)

1. F1. Fully vested.
2. F2. 25% of the shares subject to such option vest and become exercisable on May 18, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
3. F3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
4. F4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
5. F5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ProQR (PRQR) director Theresa Heggie report on this Form 3?

Theresa Heggie reports her existing equity holdings in ProQR, including multiple option grants and Ordinary Shares. These entries are holdings, not new market trades, and outline her direct option positions plus her 43,623 directly held Ordinary Shares as of the reported date.

How many Ordinary Shares does Theresa Heggie hold directly in ProQR (PRQR)?

Theresa Heggie holds 43,623 Ordinary Shares directly. This share position is reported separately from her option awards and represents stock already owned, rather than rights to buy in the future under the disclosed share option grants.

What are the key option positions disclosed by Theresa Heggie in ProQR (PRQR)?

She reports several "Share Option (Right to Buy)" positions on Ordinary Shares, including 100,000 underlying shares at an exercise price of $6.73 expiring October 31, 2033, plus other grants with exercise prices between $0.67 and $9.91 and expirations running from 2029 to 2035.

Are any of Theresa Heggie’s ProQR (PRQR) options fully vested?

One option grant is described as fully vested in the footnotes. Other grants vest 25% on specified start dates, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service with ProQR on each vesting date.

Do the Form 3 entries for ProQR (PRQR) show insider buying or selling by Theresa Heggie?

The entries are classified as holdings, with no buy or sell transactions indicated. They describe her existing options and share ownership, including exercise prices and expirations, rather than new open-market purchases or sales of ProQR Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

HEGGIE THERESA

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	43,623	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	10/31/2033	Ordinary Shares	100,000	$6.73	D
Share Option (Right to Buy)	(1)	06/30/2029	Ordinary Shares	13,334	$9.1	D
Share Option (Right to Buy)	(1)	12/31/2029	Ordinary Shares	24,615	$9.91	D
Share Option (Right to Buy)	(1)	12/31/2030	Ordinary Shares	23,239	$4.2	D
Share Option (Right to Buy)	(1)	02/29/2032	Ordinary Shares	78,556	$1.02	D
Share Option (Right to Buy)	(1)	04/30/2032	Ordinary Shares	80,594	$0.67	D
Share Option (Right to Buy)	(2)	05/17/2033	Ordinary Shares	14,418	$1.74	D
Share Option (Right to Buy)	(3)	12/31/2033	Ordinary Shares	23,489	$1.98	D
Share Option (Right to Buy)	(4)	12/31/2034	Ordinary Shares	22,128	$2.65	D
Share Option (Right to Buy)	(5)	12/31/2035	Ordinary Shares	25,192	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on May 18, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)